<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Risk of <z:hpo ids='HP_0001297'>stroke</z:hpo> and <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> (TE) in patients with non-valvular <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (NVAF) is categorised in <z:hpo ids='HP_0001297'>stroke</z:hpo> risk stratification scores </plain></SENT>
<SENT sid="1" pm="."><plain>The role of pattern of NVAF in risk prediction is unclear in contemporary 'real world' cohorts </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: Patients with NVAF in a four-hospital-institution between 2000 and 2010 were included </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0001297'>Stroke</z:hpo>/TE event rates were calculated according to pattern of AF, i.e. paroxysmal, persistent and permanent </plain></SENT>
<SENT sid="4" pm="."><plain>Risk factors were investigated by Cox regression </plain></SENT>
<SENT sid="5" pm="."><plain>Among 7156 NVAF patients, 4176 (58.4%) patients with paroxysmal, 376 (5.3%) with persistent and 2604 (36.3%) with permanent patterns of NVAF were included </plain></SENT>
<SENT sid="6" pm="."><plain>In non-anticoagulated patients, overall <z:hpo ids='HP_0001297'>stroke</z:hpo>/TE event rate per 100 person-years was 1.29 (95% CI 1.13-1.47) </plain></SENT>
<SENT sid="7" pm="."><plain>Compared with paroxysmal NVAF, rates of <z:hpo ids='HP_0001297'>stroke</z:hpo>/TE, <z:mp ids='MP_0001914'>bleeding</z:mp> and <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality (p&lt;0.001) were significantly higher in permanent NVAF patients but not in persistent NVAF patients </plain></SENT>
<SENT sid="8" pm="."><plain>In multivariate analyses, previous <z:hpo ids='HP_0001297'>stroke</z:hpo> (hazard ratio, HR 2.58, 95% CI 2.08-3.21), <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> (HR 1.34, 1.12-1.61), <z:hpo ids='HP_0001635'>heart failure</z:hpo> (HR 1.20, 1.00-1.44), ageâ‰¥75years (HR 2.75, 2.16-3.50) and age 65-74years (HR 1.60, 1.22-2.09) independently increased <z:hpo ids='HP_0001297'>stroke</z:hpo>/TE risk, but not persistent (HR 1.13, 0.76-1.70) and permanent (HR 1.44, 0.96-2.16) NVAF patterns </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: In this large 'real world' NVAF cohort, rates of <z:hpo ids='HP_0001297'>stroke</z:hpo>, TE, <z:hpo ids='HP_0011420'>death</z:hpo> and <z:mp ids='MP_0001914'>bleeding</z:mp> differed significantly by patterns of NVAF </plain></SENT>
<SENT sid="10" pm="."><plain>However, only previous <z:hpo ids='HP_0001297'>stroke</z:hpo>, age, <z:hpo ids='HP_0001635'>heart failure</z:hpo> and <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> (not pattern of NVAF) independently increased risk of adverse outcomes in multivariate analyses </plain></SENT>
<SENT sid="11" pm="."><plain>Thus, <z:hpo ids='HP_0001297'>stroke</z:hpo> risk is similar across <z:hpo ids='HP_0000001'>all</z:hpo> patterns of NVAF and antithrombotic therapy should be based on clinical risk factors, not on <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> pattern </plain></SENT>
</text></document>